Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Naltrexone Augmentation of Nicotine Patch Therapy - 1

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00218153
First received: September 16, 2005
Last updated: November 3, 2005
Last verified: September 2005

September 16, 2005
November 3, 2005
November 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00218153 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Naltrexone Augmentation of Nicotine Patch Therapy - 1
Naltrexone Augmentation of Nicotine Patch Therapy

Naltrexone Augmentation of Nicotine Patch Therapy

This double blind placebo controlled study is designed to determine whether naltrexone can be used to help reduce cigarette use and craving for cigarettes. Eligible participants will receive 21mg transdermal nicotine as an outpatient. In addition, participants will receive one of three doses of naltrexone (25,50 or 100mg) or a placebo and brief counseling over the course of six weeks with follow-up appointments three, six, and twelve months after the beginning of treatment.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Tobacco Use Disorder
Drug: Naltrexone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
April 2004
Not Provided

Inclusion Criteria:

  1. Age 18 and older
  2. Willingness and ability to give written consent
  3. Smoking 20 cigarettes per day for at least 1 year
  4. At least one prior attempt to stop smoking
  5. Baseline expired carbon-monoxide level of at least 10 ppm
  6. Weigh at least 100 lbs.
  7. English speaking
  8. One person per household

Exclusion Criteria:

  1. Pregnant or nursing women or women who do not use a reliable form of birth control
  2. Unstable cardiac disease
  3. History of dermatoses
  4. Current alcohol dependence
  5. Current use of opiates
  6. A urine drug screen that is positive for opiates
  7. Serious current neurologic, psychiatric or medical illness
  8. Chronic pain conditions necessitating opioid treatment
  9. Evidence of significant hepatocellular injury as evidence by SGOT or SGPT >3 x normal or elevated bilirubin
  10. Current use of smokeless tobacco, pipes, cigars, nicotine gum or nicotine patch
  11. Patients requiring concomitant therapy with any psychotropic drug or on any drug with a psychotropic component
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00218153
NIDA-13334-1, P50-13334-1
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Stephanie O'Malley, Ph.D. Substance Abuse Treatment Unit
National Institute on Drug Abuse (NIDA)
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP